

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding HER2-low breast cancer?**
 - This subtype accounts for about half of all breast cancer cases
 - Trastuzumab has demonstrated significant activity in patients with HER2-low breast cancer
 - Trastuzumab deruxtecan is not effective in patients with HER2-low breast cancer
- 2. Which of the following drug types best describes the novel agent zenocutuzumab under investigation for HER2-low breast cancer?**
 - Antibody-drug conjugate
 - Bispecific antibody targeting HER2 and HER3
 - Chimeric antigen receptor T-cell therapy
- 3. Which of the following statements is FALSE regarding trastuzumab duocarmazine?**
 - It is an antibody-drug conjugate with a DNA-alkylating payload
 - It may be associated with ocular toxicity
 - It has not demonstrated activity in patients with HER2-low breast cancer
- 4. Which of the following statements is FALSE regarding trastuzumab deruxtecan?**
 - It is an antibody-drug conjugate with a topoisomerase-1 payload
 - It does not cause a bystander effect
 - It has been associated with nausea and interstitial lung disease/pneumonitis